Vision 1 Year after Gene Therapy for Leber's Congenital Amaurosis
- 13 August 2009
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 361 (7), 725-727
- https://doi.org/10.1056/nejmc0903652
Abstract
To the Editor: Leber's congenital amaurosis, a common cause of blindness in infants and children,1 recently became the first human genetic retinal disease to show improved vision in response to treatment. Patients with mutations in the gene encoding retinal pigment epithelium–specific 65-kD protein (RPE65) had gains in vision within weeks after subretinal injection of a vector containing the gene in one eye.25 At 1-year follow-up after gene therapy, the three young adult patients in our trial4,5 remained without serious adverse events.A noteworthy observation in one patient at 1 year after treatment prompted further studies. For . . .Keywords
This publication has 5 references indexed in Scilit:
- Treatment of Leber Congenital Amaurosis Due toRPE65Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I TrialHuman Gene Therapy, 2008
- Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kineticsProceedings of the National Academy of Sciences, 2008
- Leber congenital amaurosis: Genes, proteins and disease mechanismsProgress in Retinal and Eye Research, 2008
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisNew England Journal of Medicine, 2008